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1. Introduction 
Cancer stem cells (CSCs) are believed to be responsible for tumor initiation and development, 
metastasis and resistance to radio-therapy and a priori to numerous natural or synthetic 
chemical compounds. A large body of observations support now the 100 year old hypothesis 
which predicted a clonal genetic background of the heterogeneous cell population found in 
a tumor outgrowth [Paget, 1889]. Accordingly, since Dick's laboratory pioneering work in 
1994 [Lapidot et al., 1994], growing realizations suggest that CSCs arise from embryonic, 
fetal or adult stem cells (SCs) or closely related dedifferentiated descendants. Interestingly, 
the concept that CSCs give rise to the bulk cancer cells is in accordance with the germ theory 
of disease developed by Koch in the 19th century [Garcion et al., 2009]. This theory points 
out that any disease has a unique causative agent. Although Koch’s dogma suggests that 
tumors should arise from CSCs, it must also be borne in mind that their descendant cancer 
cells can generated dedifferentiated cells with a parental phenotype and therefore can be 
involved in the outburst of a secondary cancer. 
On the basis of epidemiological data, it has been recurrently reported that diet rich in fruits 
and vegetables has cancer-protective properties; this suggests that plant-derived compounds 
are able to restrict the expansion of CSCs and even to kill them. The chemotherapeutic benefits 
of different natural or synthetic phytochemical agents on cancer cells are well documented. 
However their effects on CSCs are poorly understood, to a large extent because on the 
absence of well characterized experimental models. The objective of this chapter is therefore 
to recapitulate some aspects of the biology of CSCs and to propose different cellular tools 
and molecular preys for thorough pharmacological studies on CSCs, on the basis of the most 
recent data concerning the stemness factor Oct4. After reviewing known effects of specific 
phytochemicals on CSCs, we will focus on related promising strategies which could target 
the Achilles’ heel of CSCs, in particular those harboring a selective sensitivity to oxidative 
stress and/or present in weakly differentiated Oct-4 expressing cancers. 
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2. Overview of cancer stem cell biology 
2.1 Properties of cancer stem cells 
CSCs share many characteristics with SCs and can be defined by their capacity to undergo 
self-renewal and to differentiate into more or less restricted cell types (from pluripotency to 
monopotency), depending on their embryological origins. The ability to self-renew allows 
the expansion of either the SCs or CSCs pool, in response to controlled or uncontrolled 
systemic and local signals respectively. Cell self-renewal involves either an asymetric or a 
symetric division process and allows the production of two daughter cells, one being 
identical to the mother cell and the second being expected to lose some of its lineage-specific 
competencies [Morrison & Kimble, 2006]. Actually differentiation from the SC or CSC 
compartment involves a sequential production of cells with more and more tissue-specific 
spezialization [Lobo et al., 2007; Sell, 2004]. Interestingly the level of aggressiveness of the 
CSCs seems to be related to their state of differentiation; poorly differentiated cells are 
highly aggressive while nearly terminally differentiated cells only give rise to benign tumors 
(Fig. 1). Since the fine balance between proliferation and differentiation is expected to be 
corrupted in CSC, it can be hypothesized that the biological chaos will be even more 
pronounced when a CSC exhibits a higher proliferation rate for a longer retention time until 
its final differentiation. 
In view of its properties, a CSC can be firmly distinguished from a cancer cell by its unique 
capacity to undergo differentiation. However both of these cell types have enhanced growth 
ability which can be closely correlated with elevated levels of glycolysis and increasing 
metabolic activity. This property, previously described by Warburg, is considered as one of 
the most fundamental alterations occurring during malignant transformation [Warburg, 
1924]. Adversely it has been postulated that a given CSC could originate from a cancer cell 
(or a CSC with lower lineage-specific competencies) which dedifferentiates into a stem-like 
cell (or into a CSC with higher lineage-specific competencies). Although dedifferentiation 
has not yet been identified as a naturally occurring process, an increasing number of reports 
assume the concept of such oncogene-induced plasticity [Rapp et al., 2008; Visvader, 2011], 
recently validated by mathematical modelings [Leder et al., 2010]. 
2.2 Regulatory networks of cancer stem cells in the niche 
Accumulating evidences have shown that CSCs, like SCs, are regulated by common 
molecular pathways. Wnt/beta-catenin, Notch and Hedgehog pathways have been shown 
to be involved in the self-renewal regulation of both SCs and CSCs [Blank et al., 2008; Lobo 
et al., 2007]. In particular, Wnt signaling is known to promote proliferation of SCs when it 
binds its receptor Frizzled; a negative signal is then sent to inhibit the activity of APC 
(Adenomatous Polyposis Coli) which controls the degradation of beta-catenin. Increased 
amount of stabilized cytoplasmic and consequently nuclear catenin triggers then cell growth. 
Accordingly, accumulation of beta-catenin has also been frequently reported in various 
cancer cell types [Reguart et al., 2005]. Mice expressing constitutively activated beta-catenin 
showed highly proliferative tumors. Nevertheless apart their incidence on SC/CSC 
proliferation, an impaired activity of Wnt, Notch and/or Hedgehog pathways should also 
interfere with SC/CSC competency and its differentiation capacity. Indeed the balance 
between proliferation and differentiation for a proper self-renewal is difficult to determinate, 
as observed for example by the dual role of Wnt in both cell processes. A growing body of 
reports suggests that Wnt signaling can provide instructive signals that change the 
www.intechopen.com
Towards New Anticancer Strategies by  
Targeting Cancer Stem Cells with Phytochemical Compounds   
 
433 
commitment of SCs [Angers & Moon, 2009]. Given that different Wnt and Frizzled proteins 
can lead to the activation of either a catenin-dependent or -independent pathways, it seems 
obvious that these latter could somehow influence the cell fate of both SCs and CSCs. 
 
 
Fig. 1. Hierarchical and dynamical relationships between SCs, CSCs and their descendants. 
By successive differentiation waves, SCs lose step by step their cell competencies and 
become highly specialized cells. Stress-induced mutation and/or dominant proliferating 
signals trigger the transformation of SCs, committed to a specific fate, into CSCs which share 
the same differentiation profile. Uncontrolled proliferation of their homeless descendants 
leads to the outburst of a tumor which malignancy depends upon the differentiation stage of 
the tumor-initiating cells. Additional oncogenic hit likely allows CSC descendants to 
dedifferentiate into cells which possess higher lineage-specific competencies. The different 
types of SCs (and their corresponding CSCs) harbor distinct phenotypic markers (depicted 
by A to D) and show differential self-renewal capacity (depicted by faint to thick semi-
circular arrows) 
CSCs, in contrast to SCs, are not able to control their own population size. This suggests that 
the homeostatic regulation of CSCs by the niche is impaired. Indeed SCs are known to be 
anchored to niches found in a limited and specialized microenvironment of the different 
organs in the body (Fig. 1). Usually these cells are quiescent and are devoted for 
replenishing dead cells and repairing damaged tissues ; however SCs may be transformed in 
activated CSCs when exposed to repetitive mutation-inducing stress injuries without any 
ability to escape throughout the cell flux or to undergo apoptosis. Leaving their dormant 
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state, CSCs poised by failures of the self-renewal system and unable to respond in an 
appropriate manner to Wnt, Notch or Hedgehog signals, may then proliferate without 
restraint and escape from the niche, leading to the outburst of the tumor. However it has 
also been hypothesized that alteration of the niche by dominant proliferation-promoting 
signals could explain why SCs lost the dependance for limited expansion and become 
uncontrolled with a higher risk of oncogenic drift [L. Li & Neaves, 2006]. Thus restoring the 
regulatory signaling pathways in the niche might be a promising strategy to keep CSCs in 
check. 
2.3 Models for studying cancer chemoprevention: identification of CSC markers 
A direct consequence of the existence of CSCs assumes that future anticancer treatments 
should target this cell population. It is therefore critical to better characterize them. Some 
markers, like the cell surface antigen CD133, have been recommended for a prospective 
isolation of CSCs (Table 1). However recent studies have indicated that CD133 is also 
expressed in differentiated normal cells of various organs and CD133-negative cancer cells 
can also initiate tumors [Salnikov et al., 2009]. In this point of view, a very convincing report 
has clearly shown that a hierarchy of self-renewing CSC types expressing or not CD133 can 
be identify in glioblastoma tumors [Chen et al., 2010]. Therefore the relative reliability of 
such markers in CSCs, and consequently the absence of bona fide CSCs lines, remains a main 
barrier for studying the effects of potential cancer chemopreventive agents. For that purpose, 
commonly used chemical carcinogens were also used to initiate tumors of specific cell types; 
moreover the question of interlaboratory variability and standardization still remains 
 
Tissue Marker Description Reference 
 Brain CD133 (Prominin 1) Transmembranic
Prestegarden &  
Enger, 2010 
 Breast CD44 (Homing Cell Adhesion Molecule) Transmembranic
Garvalov &  
Acker, 2011 
 Colon CD24 (Heat-Stable Antigen) GPI-anchored 
Todaro  
et al., 2010 
 Ovary CD117 (c-Kit) Transmembranic
Garvalov &  
Acker, 2011 
 Pancreas CD326 (Epithelial-Specific Antigen –ESA-) Transmembranic
C. Li  
et al., 2009 
 Prostate Prostate Stem Cell Antigen (PSCA) GPI-anchored 
Saeki 
et al., 2010 
 Testis CD9 (Tetraspanin 29) Transmembranic
Biermann  
et al., 2007 
Table 1. Frequently recommended cell surface marker for the detection and isolation of 
CSCs in various tissues. Some additional markers are routinely used to purify CSCs to 
homogeneity (Keysar & Jimeno, 2010), like CD44 for colorectal cancer or CD133 for breast 
carcinoma. It should be noticed that CD44 is recurrently mentioned as a reliable marker of 
any type of CSCs. Moreover the marker expressed in tumor-initiating cell denotes more 
precisely the embryonic origin of the cell than the tissue where it developped [Visvader, 
2011]. GPI: glycosylphosphatidylinositol. (Prestegarden & Enger, 2010) 
www.intechopen.com
Towards New Anticancer Strategies by  
Targeting Cancer Stem Cells with Phytochemical Compounds   
 
435 
to be solved [Rosenberg et al., 2009]. Within the framework in this debate, embryonic stem 
cell lines (and their malignant counterparts, the embryonal carcinoma stem cell lines) are 
expected to be suitable models of CSCs and can be used as surrogated investigational tools 
for thorough evaluation of potential anticancer chemopreventive agents. Accordingly, 
numerous available teratocarcinomal cell lines were obtained after serial xenotransplantation 
and cultivation; such experimental design allows the recapture of the malignant phenotype 
and is widely used to isolate CSCs from any tumor tissue [Sell, 2004]. 
2.4 The Oct4 mystery 
2.4.1 Regulation of Oct4 expression in stem cells 
Oct4 (also known as POU5F1), a member of the POU-domain family of transcription factors, 
plays an essential role in the maintenance of embryonic stem cell potency and the 
establishment of the germ cell lineage. In embryonic stem cells, an Oct4 expression level 
between 50% and 150% of the endogenous amount appears to be permissive for self-renewal 
and maintenance of cell potency. Oct4 is downregulated during gastrulation when SCs 
differentiate, and eventually its expression is confined to the germ cell lineage. Consistent 
with its expression profile, it has been shown that Oct4 is active in embryonic stem cells, 
embryonal carcinoma cells and embryonic germ cells (Fig. 2). Upon treatment with retinoic 
acid (RA), these cells differentiate and Oct4 is rapidly downregulated [Pesce & Schöler, 
2001]. 
Finely tuned functional Oct4 levels are crucial for phenotype stability and it is believed that 
the induction or repression of Oct4 is heavily regulated in order to avoid any deleterious 
effect of a transient dysfunction. It has been shown that the regulation of Oct4 expression 
involves different members of the nuclear receptor superfamily, including SF-1 
(Steroidogenic Factor 1), LRH-1 (Liver Receptor Homolog-1) and GCNF (Germ Cell Nuclear 
Factor) [Kellner & Kikyo, 2010]. By means of genetic, molecular, and pharmacological 
studies, a recent report has demonstrated that a catenin-dependent LRH-1 regulation is 
required for maintaining steady-state levels of Oct4 [Wagner et al., 2010]. This means that 
the balance between proliferation and differentiation of pluripotent SCs involves, at least in 
part, a Wnt/beta-catenin control which can specifically target the upstream regulators of the 
stemness factor Oct4. Moreover it has been argued that GCNF is able to recruit different 
MBD (Methylated CpG Binding Domain) proteins to the Oct4 promoter, suggesting a link 
between Oct4 gene repression and its epigenetic locking [Gu et al., 2006]. A cascade of 
events from the binding of extracellular signaling molecules to Oct4 gene silencing can 
therefore be outlined. However additional as yet unknown mechanisms of regulation might 
also emerge in the future. 
MicroRNAs (miRNAs) are known to regulate posttranscriptionally a target, by pairing with 
a short antisense stretch located in the 3′-untranslated region of its mRNA, in order to affect 
its stability and/or translation. A recent report has shown that miR-145 binds to Oct4 
mRNA, represses its expression and induces lineage-restricted differentiation of embryonic 
SCs [N. Xu et al., 2009]. Intriguingly, three other miRNAS, e.g. miR-134, miR-296 and miR-
470, have been described to target in the amino acid coding sequence of Oct4 mRNA, 
leading to transcriptional and morphological changes of the pluripotent SCs [Tay et al., 
2008]. Theses observations demonstrate therefore that the levels of Oct4 can be indirectly 
regulated by different naturally occurring miRNAs and that these latter can induce a 
phenotypic switch of SCs from a highly pluripotent to a more restricted state. 
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Fig. 2. Recapitulation of in vivo and in vitro expression of Oct4-related proteins in human SCs 
and CSCs. Oct4 is highly expressed in the inner cell mass of the blastocyst; at day 35 of the 
embryonic development, the expresion of the protein is confined in the germ cells, which 
will later on invade the genital ridges. Cultivated embryonic stem cells from the blastocyst 
give rise to different cell types which do not express Oct4. Extensively cultivated somatic 
cells might express Oct4 to a limited extent, but their ability to acquire stem-like properties 
remains questionable. An Oct4 signature can be identified in numerous cancer cells; 
depending upon the experimental method used, the detectable expression of Oct4 splicing 
variants and/or pseudogene products might be artifactitious or specific of some types of 
CSCs, and therefore could be involved in the etiology of the neoplasia. The role of Oct4 
homologs (e.g. Oct1) should also be considered. Oct4 is depicted in red; the brightness of the 
color represents the amount of expression 
Oct-4 transcriptional activity is regulated at the posttranslational level by different 
mechanisms. Sumoylation by SUMO-1 (Small Ubiquitin-related Modifier, 1) increases the 
stability of the protein and its transactivation potential [Wei et al., 2007]. In contrary, its 
ubiquitination by the E3 ubiquitin-protein ligase WWP2 (WW domain-containing Protein, 2) 
promotes its degradation [H. Xu et al., 2009]. Finally the repression of Oct4 expression, at 
the transcriptional, posttranscriptional and now posttranslational level [Shi & Jin, 2010], 
implicates multiple regulators which might be potential targets for a selective ablation of 
Oct4 function. This issue will be specifically addressed in the last section. 
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2.4.2 Oct4-dependent transcriptional networks in stem cells 
As a major guardian of early stemness preservation, Oct4 regulates the transcription of 
numerous genes to maintain the self-renewal and pluripotency properties of the embryonic 
stem cells (Table 2). The POU factor interacts via its two domains POU and Hox with the 
octamer motif ATGCAAAT (or certain variants) located at the promoter(s) and/or the 
regulatory regions of the different target genes [Pesce & Schöler, 2001]. By this way, Oct4 
activates or represses genes which are associated with proliferation and differentiation 
processes. Through ChIP-on-chip analysis, more than 900 putative direct downstream 
targets of Oct4 have been identified [Jung et al., 2010]. 
 
 Target gene Protein function Cell process Reference 
CDX2 (caudal type homeobox 
transcription factor 2) 
Transcription  
factor 
Differentiation 
induction 
Babaie  
et al., 2007 
FGF4 (fibroblast  
growth factor-4) 
Signaling  
molecule 
Differentiation 
repression 
Chew  
et al., 2005 
nanog 
Transcription  
factor 
Stem cell  
identity 
Rodda  
et al., 2005 
NDUFA3 (NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex, 3)
Mitochondrial  
electron carrier 
Cell  
metabolism 
X. Chen  
et al., 2008 
Oct4 
Transcription  
factor 
Stem cell  
identity 
Chew  
et al., 2005 
p21 (WAF1 ; CIP1) 
Cyclin-dependent  
kinase inhibitor 
Proliferation 
inhibition 
Lee  
et al., 2010 
SOX2 
Transcription  
factor 
Stem cell  
identity 
Chew  
et al., 2005 
TP53 (p53) 
Tumor  
suppressor 
Cell death 
Campbell  
et al., 2007 
 SUZ12 (suppressor of zeste 12 
 homolog) 
Polycomb repressive
complex 2 
Chromatin 
remodeling 
Sharov  
et al., 2008 
Table 2. Representative set of genes targeted by Oct4. The above mentioned downstream 
effectors of Oct4 were selected on the basis of experimental evidences, mainly involving 
functional genomic analysis after loss of Oct4 function. Note that nanog, Oct4 and SOX2 are 
also transcriptionally regulated by Oct4, pointing out the crucial role of the POU factor in 
the maintenance of a stemness profile in embryonic stem cells. By targeting genes involved 
in cell growth and differentiation, Oct4 enables an efficient and proper self-renewal of 
undifferentiated cells 
To achieve a higher specificity, Oct4 may form protein complexes with other transcriptional 
regulators, including the homeobox protein nanog and the SRY-related HMG-box protein 
SOX2. Indeed large-scale mapping studies interrogating the binding sites of these three 
transcription factors showed their co-occupancy on distinct sets of target genes, suggesting 
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that their assembly in multiprotein complexes could serve as a mechanism for directing 
specificity by regulating stem cell-related gene expression [Boyer et al., 2005]. 
Interestingly, a growing body of observations highlights new insights about Oct4 activity in 
SCs and particularly in embryonic stem cells. Some candidates transcriptionally regulated 
by Oct4 are miRNAs. As an example, the POU factor binds to the promoter region of the 
miR-302 cluster in pluripotent cells, inducing an transcriptional activation of the miR-302s 
and the translational repression of its corresponding targets, such as the cell cycle regulator 
cyclin D1 [Card et al., 2008]. Interestingly miR-302 members are predicted to target many 
cell cycle regulators, suggesting that Oct4 could indirectly be implicated in the control of the 
different cell cycle checkpoints. More recently, it has been shown that Oct4 regulates the 
expression of miR-106b family members which target p21 mRNA at its 3′ untranslated 
region and thus indirectly p21 levels [Koster et al., 2010]. These observations first suggest an 
unconventional supplementary link between Oct4 and cell cycle regulation in highly 
undifferentiated SCs. It can also be expected that in the future an increasing number of 
miRNA genes might be identified as targets of Oct4. 
2.4.3 Oct4-related proteins in stem cells and cancer stem cells 
The human Oct4 gene comprises five exons. Two isoforms generated by alternative splicing, 
namely Oct4A and Oct4B, have been identified. Both have identical DNA-binding domains 
and C-terminal transactivation domains. Oct4A (i.e. Oct4) is localized in the nucleus while 
Oct4B is mainly localized in the cytoplasm and therefore should not be able to sustain self-
renewal [Cauffman et al., 2006; Lee et al., 2006]. On the other hand, five different 
pseudogenes (numbered Oct4-pg1 to Oct4-pg5) have been evidenced by whole-genome 
analysis and are highly homologous to the parental Oct4 gene [Pain et al., 2005]. In view of 
their structure, these pseudogenes can theoretically be transcribed and translated and 
therefore could participate unexpectedly in some physiological or physiopathological 
processes. The plethora of Oct4 isoforms and Oct4 pseudogene products should therefore be 
carefully taken in account when a putative Oct4 signature is expected to be detected in a 
specific type of SCs or CSCs (Fig. 2). Recently some in vivo studies have reported the 
detection of the stemness factor Oct4 in a variety of somatic tissue-derived cells, but these 
observations seem to be related to experimental pitfalls. However it cannot be excluded that 
somatic cells cultured for extensive periods of time could reactivate Oct4 function [Lengner 
et al., 2008]. The discussion that this reflects or not physiological processes to maintain 
somatic SCs in a self-renewal mechanism is still open. 
Although the transcription factor Oct4 is known to be essential for pluripotency 
maintenance and self-renewal, its expression in putative CSCs, like that of CD133, remained 
controversial in the past years [Liedtke et al., 2008]. However growing body of evidences 
support now the idea that Oct4 could be expressed in CSCs from diverse tumor origin 
[Kang et al., 2009]. Oct-4 expression is clearly associated with bladder carcinogenesis [Atlasi 
et al., 2007] and germ cell malignancy [Cheng et al., 2007]. It should be noted that, as 
nongerminomatous germ cell tumors, embryonal carcinomas and their derived cell lines, are 
therefore expected to be suitable experimental models for studying the biology of Oct4-
positive CSCs. Similarly a pluripotency gene expression signature has been evidenced in 
poorly differentiated and highly aggressive cancers [Ben-Porath et al., 2008]. Since this 
stemness identity involves Oct4 and its two coregulators, e.g. nanog and SOX2, it can be 
assumed that the regulatory networks controlling the activity of SCs are also functional in 
some cancers. Interestingly, the three proteins seem to be present even in far developmentally 
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related adult tumors, suggesting that the bulk cancer cells were able to dedifferentiate to a 
less restricted competency state. 
Intriguingly, it has been shown that breast carcinoma and glioma can express Oct4 
pseudogenes; however it seems that their products lack Oct4-like activity on the basis of 
their absence of transcriptional activation potential on known Oct4-responsive luciferase 
constructs [Zhao et al., 2011]. This suggests that the detection of Oct4 pseudogenes could 
have led to misinterpretation of some previous studies claiming the presence of Oct4 in CSC 
subtypes. Further investigations are thus necessary in order to address this issue and to 
solve whether Oct4 splicing variants and pseudogene products might be involve in SC 
identity and in the etiology of certain cancers (Fig. 2). Moreover a possible role of some Oct4 
homologs in the induction of the neoplasic process has been recently emphasized; Oct1, like 
Oct4, binds to the same DNA sequences, regulates common target genes and are under the 
control of identical upstream regulators. It is therefore hypothesized that Oct1 or other Oct 
proteins might carry out similar malignancy functions as Oct4 [Kang et al., 2009]. 
3. Phytochemicals and cancer stem cells 
Epidemiological studies have consistently linked the intake of fruits and vegetables with 
reduced risk of initiation and development of cancer [Steinmetz & Potter, 1996]. Adversely, 
recent reports based on large propective studies downgraded the previous conclusions; the 
potential chemopreventive effects of diets rich in fruits and vegetables seem to be rather 
associated with healthy nutritional principles [Key, 2011]. However it is still believed that 
particular constituents in certain fruits and vegetables could have benefit effects. More than 
three-fourths of the anticancer compounds are either derived substances from natural 
products or the natural products themselves, mostly originating from herbal medicinal and 
dietary plants or from microbial sources. This section will therefore only focus on the cancer 
chemoprotective effects of some plant-derived compounds which chemical structure is 
known. 
In a strict sense, phytochemicals with chemopreventive properties hinder the (re)appearance 
of a cancer by targeting CSCs, whereas phytochemicals with chemotherapeutic properties 
destroy a preexisting cancer by targeting cancer cells. However these latter can conceptually 
be considered, at least in part, as potential CSCs with very limited cell competencies (see 
Fig. 1). For that reason, chemotherapy and chemoprevention become hard to distinguish to 
each other, since they can theoretically target the cancer cell as well as the CSC. It is 
therefore not surprising that numerous plant-derived compounds might act on both cell 
types and have therapeutic and preventive effects [Aggarwal et al., 2004]. 
3.1 Targeting cancer cells by phytochemicals 
3.1.1 Generalities 
There is a plethora of in vivo and in vitro studies which have highlighted the benefits of 
phytochemicals against distinct cancer types. An exhaustive list of plant-derived compounds 
with known chemotherapeutic properties can be found elsewhere [Kawasaki et al., 2008; 
Shu et al., 2010]. By modulating multiple signaling pathways, they can target various cell 
processes, including induction of apoptosis as well as inhibition of cell survival, metastasis 
and angiogenesis. Such pleiotropic activity is for instance displayed by curcumin [Das et al., 
2010]; this potent polyphenol antioxidant was originally extracted from tumeric, a spice 
made from the root of the plant Curcuma longa and which is widely consumed in the Indian 
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subcontinent countries. Curcumin is one of the most studied phytochemical compound and 
will be used as a referential model for the next issues. 
It is worth noting that several plant-derived compounds are able to reverse the multidrug 
resistance (MDR) phenotype, usually observed in aggressive subpopulations of cancer cells. 
This pathological phenomena results from an intrinsic dysfunction of different energy-
dependent transporter proteins (for example P-glycoprotein or member of the multidrug 
resistant-associated proteins) which are involved in drug entry and efflux [Molnár et al., 
2010]. By down-regulating the expression of transporter proteins, some phytochemicals, like 
curcumin, can restore the chemosensitization in drug-resistant cancer cells [Limtrakul, 
2007]. 
3.1.2 Molecular targets of apoptosis-inducing chemotherapeutic phytochemicals 
Acquired resistance towards apoptosis is the key hallmark of all types of cancer [Hanahan & 
Weinberg, 2000]. Apoptosis is induced by both intrinsic (mitochondrial) and extrinsic (death 
receptor) pathways (Fig. 3). It is accompanied by successive biochemical events and 
morphological changes, like DNA condensation and fragmentation, cell shrinkage, 
membrane blebbing and membrane-associated apoptotic bodies [Saraste & Pulkki, 2000]. 
Curcumin is a very potent inducer of apoptosis and interferes with both the intrinsic and 
extrinsic proapoptotic signaling pathways; this phytochemical can therefore kill a wide 
variety of cancer cells, even if they exhibit some mutation(s)-induced failures in several 
steps of their proapoptotic machinery [Ravindran et al., 2009]. 
Apoptosis and cell survival are tightly associated in order to maintain cell population in a 
healthy homeostatic state. There are several points of crosstalk between the two operating 
systems. As a consequence, prosurvival signals increase the expression and/or the activity 
of antiapoptotic regulatory proteins, while repressing the expression and/or the activity of 
proapoptotic factors. At the opposite, proapoptotic signals activate the function of 
antisurvival molecules and inhibit the function of prosurvival factors. Such duality of action 
can be achieved because the two regulatory networks share common molecular targets. One 
of the most studied crosstalk between life and death signaling pathways is illustrated by the 
nuclear factor-κB (NF-κB). This DNA-binding protein participates in a dual role, wherein it 
mediates both prosurvival and proapoptotic signals. Actually the NF-κB pathway targets 
antiapoptotic and proapoptotic factors; depending upon the cellular context, its transcriptional 
competencies are modulated by specific upstream activators, like the serine/threonine 
protein kinase AKT or the FasL/TNF/TRAIL (Fas Ligand/Tumor Necrosis Factor/Tumor 
necrosis factor-Related Apoptosis-Inducing Ligand) death receptors [Jin & El-Deiry, 2005]. 
Such yin and yang connection can also be observed between the survival factor AKT and the 
tumor suppressor p53, or between NF-κB and p53 which competitively interact with the 
nuclear coactivators CBP/p300 (CREB-Binding Protein, related p300) and therefore 
reciprocally repress their activity [Dey et al., 2008]. 
Heat-shock proteins (HSP) are the significant integrators of the interconnective activity of 
the proapoptotic and prosurvival signaling networks. For instance, the chaperone protein 
HSP90 interferes with the function of several factors (e.g. p53) of the intrinsic and extrinsic 
apoptosis pathways, leading to cell death inhibition [Walerych et al., 2004]; HSP90 also 
promotes cell survival through its involvement in the formation of active NF-κB and the 
maintenance of AKT in its active phosphorylated form [Arya et al., 2007]. Taken together, all 
these findings might ultimately result in the development of highly efficient chemotherapeutic 
candidates which are able to target the upstream integrators, as well as several nodal points 
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of the pro-apoptotic and pro-survival machineries. In view of its widespread biological 
properties, curcumin should be considered; it is capable to disrupt HSP90 function [Wu et 
al., 2006], to upregulate p53 expression and to inhibit NF-κB and AKT activities [Ravindran 
et al., 2009]. However additional studies are needed to gain the full insights of the multifocal 
activity of curcumin and to identify the different proapoptotic and prosurvival crosstalk 
mechanisms that it can target. 
 
 
Fig. 3. Simplified scheme of the activity of a generic phytochemical on the different pro-
apoptotic and cell survival-associated pathways. In response to a cellular stress generated 
by a phytochemical, two inter-connected proapoptotic pathways can be induced. The 
extrinsic pathway is initiated by an activation of the death receptors (Fas, TNF-R, TRAIL-R) 
and triggers a caspase 8-dependent apoptosis. The intrinsic signaling pathway is driven by 
the tumor suppressor p53 (or the p53-homolog p73), a main regulator of cell cycle 
progression; the DNA-damage induced activation of p53 initiates a caspase-independent 
(CICD) or caspase 9-dependent (CDCD) cell death process, associated with a mitochondrial 
release of either the chromatinolytic factor AIF (Apoptosis-Inducing Factor) or cytochrome 
C respectively. Finally the cleavage of pro-caspase 3 in its active subunits leads to 
proteolysis and programmed cell death (PCD). The functional repression of the survival 
receptors and their effectors, e.g. AKT and NF-κB, can also trigger apoptosis. It is worth 
noting that the death receptors are also implicated in the regulation of NF-κB pathway. 
HSP90, as an integrator of both cell survival and apoptotic activities, targets various factors 
(including those underlined in white); some of these factors repress each other’s function 
(depicted by left right circle-headed arrow). The proposed phytochemical could be for 
instance curcumin (depicted by a zigzag arrow). Detailed relationships between the 
different factors can be found elsewhere [Jin & El-Deiry, 2005; Ravindran et al., 2009; Sarkar 
et al., 2009]. Note that failures of the intrinsic proapoptotic pathway can lead to an 
accumulation of DNA damages which in turn leads to incorrect DNA repair and mutations 
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Interestingly, induction of apoptosis triggers the suppression of the angiogenic process and 
the inhibition of tumor growth [Wang & Sun, 2010]. Moreover the signals that allow a 
migratory cancer cell to invade normal tissue, promote also cell survival by suppressing 
apoptosis [Stupack, 2007]. Therefore targeting cancer cells by apoptosis-inducing 
phytochemicals indirectly interrupt tumor neovascularization and metastasis. Accordingly 
curcumin has been shown to prevent angiogenesis and cancer cell invasion, thanks to its 
antiproliferative and proapoptotic activity [Kunnumakkara et al., 2008]. Finally, this 
phytochemical, by modulating the expression and activity of a wide variety of proteins, 
exhibits a strong therapeutic efficacy and could play an important role by cutting down 
cancer incidence. It should also be noted that this reductionist approach which only focuses 
onto two interconnected processes, namely apoptosis and proliferation and understates the 
other processes is theoretically valuable. Indeed it is expected that a normal cell should be 
corrupted by at least six different mutations to be convert into a cancer cell; these mutations 
are associated with self-sufficiency towards proliferative signals, insensitivity to growth 
suppressors, resistance for cell death, ability for limitless replication, angiogenesis induction 
and metastasis activation [Hanahan & Weinberg, 2000]. However the concomitant 
occurrence of multiple mutations in any cell is statistically rare if not impossible. This 
suggests that only one or two mutations, affecting selectively the proapoptotic or/and 
growth inhibitory potential, are necessary for the normal cell to initiate tumorigenesis [L, Li 
& Neaves, 2006]. As a fact, tumor-associated mutations in a single gene, i.e. TP53, are the 
main hallmark of most human cancers [Whibley et al., 2009]. In the light of the above 
considerations, it becomes clear that targeting the main actors of crucial processes, like 
apoptosis or cell survival, by a pharmacological agent remains one of the most effective 
strategy in anticancer treatment. 
3.2 Targeting cancer stem cells by phytochemicals 
3.2.1 Generalities 
CSCs, like cancer cells, exhibit uncontrolled growth and therefore show quite similar 
susceptibility to plant-derived compounds, which should target, through their 
antiproliferative properties, common molecular pathways [Aggarwal et al., 2004]. 
Nevertheless it is expected that differentiation-inducing phytochemicals are able to 
counteract two different cell processes, namely the self-renewal maintenance which is 
specific of CSCs and the dedifferentiation drift which can affect both CSCs and cancer cells 
(see Fig. 1). 
3.2.2 Targeting selectively cancer stem cells by apoptosis-inducing phytochemicals 
A growing body of studies suggests that phytochemicals can trigger a proapoptotic response 
of potential or full-blown CSCs. For example, curcumin induces a decrease of the stem-like 
side population of the rat C6 glioma cell line, likely through a proapoptotic process [Fong et 
al., 2010]. Accordingly, curcumin activates the caspases of both the extrinsic and intrinsic 
pathways of apoptosis and represses AKT function (see Fig. 3) in various ovarian carcinoma 
cell lines [Watson et al., 2009], including the SKOV3 cell line from which a side population 
of CD133/CD117-positive cells (see Table 1) with cancer stem-like properties can be isolated 
[Ma et al., 2010]. The broccoli compound sulforaphane, a member of the isothiocyanate 
family of phytochemicals, represses NF-κB-dependent prosurvival activity of pancreatic 
CD44-positive tumour-initiating cells, leading to the downregulation of antiapoptotic 
proteins and induction of caspase activity followed by apoptosis [Kallifatidis et al., 2009]. 
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The polyphenolic compound resveratrol triggers apoptosis by activating caspase-3/7 in 
pancreatic CD133/CD44/CD24/ESA-positive CSCs isolated from human primary cancer, 
suggesting that this pharmacological agent could be used for the prevention and treatment 
of pancreatic malignant tumor [Shankar et al., 2011]. In view of these examples, it can be 
expected that numerous phytochemicals, identified as proapoptotic agents on cancer cells, 
will also be recognized in the future as killers of CSCs. The main reason for this assumption 
is that various types of tumors and cancer cell lines, previously analyzed for their reactivity 
to plant-derived compounds, contain CSCs which self-renew and express SC markers 
[Kondo, 2007]. Therefore it is likely that the described sequence of pro-apoptotic events 
induced by a specific phytochemical in a given cancer cell should also be observed in its 
corresponding initiator. Such paradigm should notably be validated for plant-derived 
compounds, like polyphenols, which act as DNA damage inducers; the canonical molecular 
cascade usually implicates an activation of the p53 or p73-dependent cell cycle checkpoint 
signaling pathway and consequently an initiation of a caspase-mediated protein 
degradation and DNA fragmentation, leading to an irreversible growth inhibition by 
enhanced apoptosis [Narayanan, 2006]. Such sequence of events, shown in cancer cells, 
might also be evidenced in CSCs. If this extrapolation is confirmed, this would finally mean 
that apoptosis-inducing phytochemicals remain very powerful weapons against cancer since 
they target both CSCs and their descendants, hereby by common pathways. 
Intriguingly some phytochemicals, in a reasonable range of concentrations, kill cancer cells 
without having any toxic effects on normal cells. This selectivity is poorly understood. 
Several explanations have been put forward. Most of tumor cells, in contrast to normal cells, 
constitutively express active NF-κB which mediates their survival [Prasad et al., 2010]. 
Phytochemicals with differential cytotoxic properties, like curcumin or the flavone wogonin, 
are known to repress the activity of NF-κB downstream targets [Li-Weber, 2009; Shishodia 
et al., 2005], thereby normalizing the exaggerated proliferation capacity of cancer cells and 
inducing their death. It is therefore tempting to think that all cancer cells exhibit a 
deregulation of NF-κB expression which could be selectively targeted by proapoptotic plant-
derived compounds. However such cause-effect relationship has to be clearly demonstrated. 
Different mechanisms which lead to a constitutive expression of active NF-κB in cancer cells 
have been suggested, including dysregulation of cytokine receptors [Prasad et al., 2010]. 
Interestingly, it is known since the early 1990s that NF-κB is a redox-sensitive transcription 
factor; its activity is upregulated by enhanced levels of ROS (Reactive Oxygen Species) 
which are tighly associated with malignant initiation and progression. However several 
studies have shown that ROS has paradoxic effects on NF-κB activity, depending upon its 
levels. Mild increase of free radicals often induces NF-κB activation and sustained cell 
survival, while a drastic increase of free radicals leads to a repression of NF-κB function and 
cell death [Trachootham et al., 2008; Trachootham et al., 2009]. Actually, intracellular ROS 
production result from several processes, including the mitochondrial oxidative 
phosphorylation which involves a set of enzymatic complexes (e.g. NADH dehydrogenase, 
succinate dehydrogenase) constituting the respiratory chain. At the opposite, enzymatic 
antioxidants (e.g. superoxide dismutases, glutathione peroxidase) or scavengers (e.g. cystein, 
albumin) contribute to regulate the levels of oxygen-free radicals in order to protect the cells 
from oxidative damage and prevent mutation-induced malignancy. According to the 
oxidant and antioxidant mechanisms involved, changes in ROS levels can either directly 
impair the DNA binding capacity of NF-κB or trigger its transcriptional activity by 
promoting its nuclear translocation [Pani et al., 2010]. 
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The redox status plays a crucial role in maintaining the cell activity under normal 
conditions. To reduce the risk of oxidative-induced mitochondrial apoptosis due to high 
proliferative-linked metabolic activity, cancer cells « adopt » a glycolytic state to the 
detriment of an oxidative state. This Warburg’s effect leads cancer cells to maintain high 
levels of free radicals, in contrast to normal cells. Although CSCs similarly show enhanced 
ROS content compared to normal SCs, these two cell types produce only a limited amount 
of oxygen radicals, likely because they reside in a low oxygen microenvironment [Diehn 
et al., 2009]. This explains why some CSCs are resistant to radiotherapy and 
chemotherapic phytochemicals which require the availability of local oxygen to develop 
their cytotoxic activity. However the redox status and adaptation displayed by the CSCs 
and their descendants, as well as by their normal counterparts is a key mechanism that, to 
a certain extent, might explain the selective cytotoxic effect of a ROS-producing plant-
derived compound. In regard to the crucial influence of redox homeostasis on the life-
and-death processes, it was suggested that an additional and robust ROS-producing stress 
could kill the adapted but easily overwhelmed cancer cells, without having toxic side 
effects on normal cells [Fruehauf & Meyskens, 2007; Trachootham et al., 2008]. It can be 
postulated by extrapolation that CSCs, in contrast to normal SCs, harbor a similar weak 
adaptation capacity of the redox machineries when exposed to oxidative stress, induced 
for instance by a cytotoxic phytochemical. A hypothetical sequence of events can then be 
set forth to explain the selective effects of a plant-derived compound on cancer cells and 
CSCs (Fig. 4). However the molecular mechanism which leads to the quenching of the 
ROS buffering capacity has still to be identified. Limited adaptability of the redox 
homeostasis might be linked to some steric hindrance of factors involved in mitochondrial 
activiy. The absolute level of the redox balance in the normal and cancer cells (or their 
progenitors) might be the key parameter which needs to be considered for expecting a 
selective cytotoxic effect of a ROS-inducing pharmacological agent. Finally the higher 
sensitivity of some SCs to DNA damage-induced mutations has lead to cancer 
transformation and consequently to an adaptative redox response which might be easily 
and selectively overwhelmed by a prooxidant phytochemical. A redox-modulating strategy 
which targets the Achilles’ heel of CSCs and their descendants could therefore have major 
implications in cancer treatment. 
It is worth noting that a notable body of studies has highlighted the dual effects of some 
phytochemicals as antioxidants and prooxidants. As antioxidant agents, they are believed to 
protect DNA integrity by quenching oxygen-free radicals produced by a pathogenic 
oxidative stress and thus should impede the transformation of injured SCs. As prooxidant 
agents, they are able to kill CSCs and their descendants by triggering an intracellular 
production of ROS. These compounds, such as the polyphenolic flavonoids, are therefore 
acting as double-edged swords by targeting the redox regulatory system. The antioxydant 
or prooxidant effect of a particular phytochemical seems mostly to be dose- and time-
dependent [Procházková et al, 2011; Schwartz, 1996]. The reason for this paradoxical activity 
of some plant-derived compound is still poorly understood. They could initially target a 
same ROS-sensing molecule which is involved in both antioxidant and prooxidant cell 
processes. The mitochondrial coenzyme Q could be such a candidate; this electron carrier is 
known to contribute to mitochondrial oxidative damage and antioxidant defenses [James et 
al, 2004]. However its precise role in the phytochemical-induced redox response of SCs, 
CSCs and their offsprings requires further studies. 
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Fig. 4. Hypothetical effects of a selective cytotoxic prooxidant phytochemical on the redox 
homeostasis of normal cells, cancer cells and their respective progenitors. Normal cell (NC) 
and normal stem cell (NSC) are able to maintain low levels of intracellular ROS by controlling 
the steady-state activity of the oxidant and antioxidant machineries (depicted respectively 
by a left and right arm of a balance); both cell types can tolerate, in a reasonable range of 
concentrations, an oxidative stress (represented as a clockwise semicircle arrow) induced by 
a phytochemical (depicted by an upwards and/or downwards thick arrow pointing either 
one or the two arms of the balance) through adaptative antioxidant responses (represented 
as an dotted anticlockwise semicircle arrow). Cancer cell (CC) and cancer stem cell (CSC) 
show increased basal levels of ROS due to exaggered metabolic activity and are more 
vulnerable to further oxidative stress induced by a ROS-generating phytochemical. Enhanced 
production of oxidants overwhelms the antioxidant capacity of both cancer cells and CSCs 
which reaches a toxic biological limit (represented as a dotted horizontal line), leading to 
death. It is assumed that the death threshold is lower in NSC and CSC than in their 
corresponding counterpart, since they reside in an autarkic microenvironment which does 
not allow detoxication exchanges. CSC chemoresistance might be associated with a 
reorientation of the oxidant and antioxidant activities towards its initial levels (depicted by a 
green line on the top of the balance). Adapted from a previous review [Trachootham et al., 
2009] 
3.2.3 Targeting cancer stem cells by differentiation-inducing phytochemicals 
3.2.3.1 Targeting the self-renewal pathways of cancer stem cells by phytochemicals 
The aggressiveness of a CSC is proportional to its lineage-specific competencies (Fig. 1). 
Moreover several studies have reported that the differentiation level of a specific type of 
CSC is inversely correlated with its resistance capacity to radiotherapy and chemotherapy 
[Al-Hajj et al., 2004]. Therefore disrupting the molecular pathways which regulate CSC self-
renewal is an attractive alternative for reducing the aggressiveness and MDR phenotype of 
the tumor bulk. By targeting these pathways, it is assumed that the CSC switches from a 
highly proliferative and undifferentiated state to a harmless low-growing and mature state. 
Accordingly, genes encoding proteins involved in Wnt/beta-catenin, Notch and Hedgehog 
signalings, are frequently mutated or aberrantly expressed in several fulminant cancers 
[Blank et al., 2008; Lobo et al., 2007]. Through direct or indirect modulation of the impaired 
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signaling pathway activities, plant-derived compounds are therefore expected to affect CSC 
self-renewal, leading to cancer regression and reduced risk of relapse. The most 
exhaustively studied differentiation-inducing pharmacological compounds are retinoids, 
including vitamin A and its derivatives. As an adjunct to clinical therapy, RA treatment 
allows complete remission of about 90% of patients with acute promyelocytic leukemia 
[Freemantle et al., 2003]. The anticancer activities of retinoids have been attributed, at least 
in part, to increased proteasomal degradation of beta-catenin, herein normalizing the 
aberrant activation of the Wnt signaling observed in some leukemias and solid tumors 
[Dillard & Lane, 2007; Mikesch et al., 2007]. This example highlights the strong positive 
impact of the differentiation strategy which is able to block the tumor burden. Actually, an 
increasing number of in vitro and in vivo studies show that various plant-derived 
compounds are potential anticancer agents since they can specifically target the self-renewal 
properties of CSCs [Kawasaki et al., 2008; Y. Li et al., 2011]. Moreover, links between 
different molecular components involved in the prosurvival and the self-renewal signaling 
pathways have been described in several reports, pointing out the fine-tuned balance which 
controls cell proliferation and differentiation [Konopleva & Jordan, 2011]. As a consequence, 
it is not surprising that some phytochemicals could act as multi-target agents by modulating 
the activity of specific nodal points of the prosurvival and self-renewal machineries [Sarkar 
et al., 2009]. All these issues will be discussed in details elsewhere (see Chapters 20 and 22). 
Reprogramming of gene expression through epigenetic modifications could explain the 
prodifferentiating anticancer activity of plant-derived compounds. The Polycomb and 
Trithorax groups of proteins are known to reverse respectively active or repressed 
transcription states of developmentally important genes during SC fate commitment 
[Ringrose & Paro, 2004]. It is therefore expected that certain differentiation-inducing 
phytochemicals could disturb the activity of these epigenetic chromatin modifiers, leading 
transiently to an active resetting of the histone code and an erasure of DNA methylation. 
This assumption is based on the fact that at least two components of the Polycomb 
multiprotein complex, namely Bmi1 polycomb ring finger oncogene and SUZ12, have been 
shown to be direct effectors of Hedgehog and Wnt signaling respectively. As such, both 
proteins are implicated in SC self-renewal and known to be upregulated in different cancers 
[Galmozzi et al., 2006]. Although some naturally-occurring inhibitors of the hedgehog and 
beta-catenin signalings can regulate CSC proliferation and differentiation by modulating a 
priori the expression of Bmi1 and SUZ12, the discussion of a direct effect of a specific plant-
derived compound on epigenetic chromatin modifiers is still open and needs further 
investigation. However several phytochemicals, including polyphenols, are able to target 
specifically several epigenetic alterations which might have led to cancer development. For 
instance, curcumin can reverse DNA hypermethylation and is suspected to reactivate 
methylation-silenced tumor suppressor genes in several colon cancer cell lines. Moreover 
curcumin, as a potent histone modifying compound, promotes the proteasome-dependent 
degradation of the histone acetyltransferase (HAT) p300/CBP in cell extracts from different 
cancer types. Such inhibitory effects is known to be associated with histone H3/H4 
hypoacetylation and repression of HAT-dependent chromatin transcription, a hallmark of a 
highly proliferative and indifferentiated cell state [Link et al., 2010]. Plant-derived 
compounds seem therefore to be promising weapons against the epigenetic disorders which 
could affect cancer cells and CSCs. However due to data scarcity, an epigenetic reorientation 
strategy for an alternative anticancer therapy remains difficult to evaluate. 
www.intechopen.com
Towards New Anticancer Strategies by  
Targeting Cancer Stem Cells with Phytochemical Compounds   
 
447 
3.2.3.2 Targeting Oct4 function in cancer stem cells by phytochemicals 
Targeting Oct4 network in poorly and aggressive Oct4-expressing cancers by phytochemical 
compounds is a very promising approach, in regard to its crucial role in stemness maintenance 
in both SCs and CSCs. On the other side, induced pluripotent stem (iPS) cell research could 
provide new insights into the mechanisms engaged during CSC differentiation. Indeed the 
current state of our knowledge in the field of cancer therapy and tissue engineering seems to 
indicate that CSC reactivity and somatic cell dedifferentiation share common molecular 
pathways in which Oct-4 could play a pivotal role (Fig. 5). 
 
 
Fig. 5. Oct4 network. Several nodes of the Oct4 pathway, active in stem cells (SC), induced 
pluripotent stem cells (iPSC) or cancer stem cells (CSC), are potential targets for plant-
derived compounds. Details relationships between the different actors can be found in 
section 2.4 of this chapter and in previous reviews [Kang et al., 2009; Shi & Jin, 2010]. 
Methylation of Oct4 promoter and specific modifications in the histone H3 code leads to a 
transcriptional repression of Oct4 
Since the pioneering work of Yamanaka’s laboratory in 2006, an exploding number of 
studies have unequivocally shown that ectopic expression of at least two transcription 
factors, namely Oct4 and SOX2, can reset the epigenome of somatic cells with restricted 
lineage-specific competencies to an highly undifferentiated pluripotent state [Feng et al., 
2009; Takahashi & Yamanaka, 2006]. However the efficiency of the reprogramming process 
still remains very low, albeit a lot of effort has been put to improve the methods. 
Interestingly, TP53 inactivation seems to facilitate significantly the embryonic SC switch, 
suggesting that a p53-mediated proapoptotic DNA damage response limits iPS cell 
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production [Marion et al., 2009]. Recently, it has been observed that reprogrammed 
pluripotent cells show genomic aberrations [Pasi et al., 2011]; this could explain why they 
can form malignant tumors when injected in donor mice [Sarig et al., 2010]. Induced Oct4-
expressing somatic cells seem therefore to adopt a SC or CSC phenotype or to undergo 
apoptosis in a stochastical manner; this firstly suggests that Oct4 is only one of the key 
decision-makers in stemness and carcinogenic behavior (see top of Fig. 5). Elucidation of the 
precise molecular mechanisms through which Oct4 maintains and reinitiates pluripotency is 
thereby necessary before planning cell therapy using iPS. An improved understanding of 
Oct4 biology will also provide a number of novel targets for the design of specific 
phytochemical therapy that aims to eradicate poorly differentiated CSCs. Different sets of 
proteins located either upstream or downstream from the Oct4 pathway have already been 
identified (Fig. 5); however the mechanisms of action of certain pharmacological agents, 
such RA, capable to target specifically Oct4-centered protein interactomes have still to be 
clearly established. For that purpose, the evaluation of a selective action of a specific plant-
derived compound on Oct4 network in CSCs has also to be considered, in regard to its 
potential side effects on normal SCs. 
4. Conclusions and future perspectives 
Conclusions of experimental data suggesting a potential biological activity of a plant-
derived compound on a specific cancer and CSC type should be carefully analyzed. In view 
of the present chapter, it seems that only phytochemicals which can selectively target the 
ROS-induced proapoptotic and/or differentiation processes, have some promising therapeutic 
values. The main reason for this assumption is that CSCs, as well as cancer cells, share a 
nearly satured adaptability of the redox capacity and escape from the signals emitted by the 
well embedded and protective niche. In regard to their susceptibility to prooxidant stresses 
and, to a certain extent, to prodifferentiation inducers, it is expected that only CSC and their 
descendants could be selectively targeted by natural or synthetic plant-derived compounds. 
One of the best example is retinoic acid which is known to be the most powerful anticancer 
agent and is used with success in chemotherapy. However dosing schedules of a considered 
phytochemical is a critical point which has to be taken in account in order to minimize and, 
if possible, to avoid toxic side effects on normal cells and their progenitors. 
Promising anticancer strategies have recently be developed by targeting CSCs. Although 
this chapter supports the anticancer benefits of phytochemical compounds, only future 
studies, likely using comparative well-defined CSC lines, will determine if they can 
reasonably act as selective chemopreventive agents in the key steps of the carcinogenic 
process. In this point of view, understanding the role of Oct4 in cancer stem cell biology is 
crucial for two main reasons. As an initial protein in the cancer cell hierarchy, and therefore 
as a reliable marker of cancer aggressiveness, its detection, as well as the available tools to 
repress its function, have strong prognostic and diagnostic values. Secondarily, as a key 
protein for somatic cell reprogramming, its controlled activity is a prerequisite for save 
immunocompetent cell regenerative therapy, without any harmful tumorigenic drift. 
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